NL

Stellantis 2023 Corporate Social Responsibility Report Outlines Strong Results Against Ambitious Dare Forward 2030 Targets

Retrieved on: 
Friday, April 5, 2024
CERN, EV, Health, Freedom, Culture, BEV, Environment, Science, Education, Blood test, Carbon, Woman, Corporate social responsibility, CSR, Mobility, Safety, Circular economy, EU27, Workplace, Government

The massive use of decarbonized electricity in the Company’s processes with a 100% target by 2030.

Key Points: 
  • The massive use of decarbonized electricity in the Company’s processes with a 100% target by 2030.
  • In 2023, it reached 58%, contributing to a 20% reduction in absolute tCO2 of the industrial carbon footprint (scope 1 and 2) vs. 2021.
  • Strong monitoring and execution of Stellantis Responsible Purchasing Guidelines: 3,461 supplier groups assessed by EcoVadis, corresponding to more than 89% of the annual purchased value.
  • Results show Stellantis suppliers are performing better on CSR criteria than the EcoVadis benchmark.

EU's reimagined NIS 2 cybersecurity vision puts businesses on high alert

Retrieved on: 
Friday, April 5, 2024
NordLayer, Health, Union, Culture, Organization, Waste management, Face, Risk management, Exercise, Network, Intelligence, Information, Cyber-security regulation, Lung compliance, Medical device

The NIS 2 aims to establish a high standard level of cybersecurity and resilience throughout the Union.

Key Points: 
  • The NIS 2 aims to establish a high standard level of cybersecurity and resilience throughout the Union.
  • "The NIS 2 represents a significant step forward in unifying and elevating cybersecurity standards across our critical economic sectors and digital infrastructure."
  • As an advocate of effective cybersecurity solutions, we are committed to enabling organizations to navigate the NIS 2 compliance journey.
  • The Network and Information Security 2 Directive (NIS 2) is an update and expansion of the original 2016 NIS Directive.

Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

Retrieved on: 
Thursday, April 4, 2024
Safety, CIIC, Abstract, HAE, Hereditary angioedema, Conference, Bradykinin receptor B2, Pharmaceutical industry

ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for presentation at the Consortium of Independent Immunology Clinics (CIIC) Spring 2024 Conference, to be held from April 12-13, 2024, in Arlington, TX.

Key Points: 
  • ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for presentation at the Consortium of Independent Immunology Clinics (CIIC) Spring 2024 Conference, to be held from April 12-13, 2024, in Arlington, TX.
  • Title: Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
    The posters and associated presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentation sessions at: https://ir.pharvaris.com/news-events/events-presentations .

Philips Foundation and March of Dimes partner to improve prenatal care access in underserved communities, helping address US maternal and infant health challenges

Retrieved on: 
Thursday, April 4, 2024
Research, Health, Partnership, Education, Patient, Hospital, Prenatal care, Mortality, Infant, Pregnancy, Birth, Woman, Community, Safety, Nursing

In comparison to other high-income countries, the US still faces the highest maternal mortality rate.

Key Points: 
  • In comparison to other high-income countries, the US still faces the highest maternal mortality rate.
  • While consistent, high-quality prenatal care is an essential component of maternal health and positive birth outcomes, more than 550,000 women receive inadequate prenatal care in the US each year.
  • Mobile healthcare delivery is a proven model to improve access to care.
  • “Every expectant mother should have access to maternal care, yet this is far from reality today.

Azerion enters into an Intercreditor Agreement and a Super Senior Working Capital Facility

Retrieved on: 
Thursday, April 4, 2024
ACT, EUR, Super Senior, Citibank Europe, AMERICA, Citibank, NOT, AS, Bank

Amsterdam, 4 April 2024 – Today, Azerion Group N.V. (the “Company”) announces it has entered into (i) an Intercreditor Agreement and (ii) a Super Senior Working Capital Facility Agreement with Citibank Europe plc (as original lender and agent), Citibank N.A., London Branch (as arranger) and Nordic Trustee & Agency AB (PUBL) (as security agent), amongst others, under which the Company is granted a EUR 15,000,000 super senior revolving credit facility (the "Super Senior Working Capital Facility").

Key Points: 
  • Amsterdam, 4 April 2024 – Today, Azerion Group N.V. (the “Company”) announces it has entered into (i) an Intercreditor Agreement and (ii) a Super Senior Working Capital Facility Agreement with Citibank Europe plc (as original lender and agent), Citibank N.A., London Branch (as arranger) and Nordic Trustee & Agency AB (PUBL) (as security agent), amongst others, under which the Company is granted a EUR 15,000,000 super senior revolving credit facility (the "Super Senior Working Capital Facility").
  • The entry into the Intercreditor Agreement and the Super Senior Working Capital Facility is as contemplated by and permitted under the terms and conditions of the EUR 165 million senior secured floating rate bonds, issued by the Company under a framework of EUR 300 million (the "Bonds").
  • Funds drawn under the Super Senior Working Capital Facility may be used by the Company for general corporate purposes including working capital and acquisitions.
  • The commercial conditions of the Super Senior Working Capital Facility are in line with market practice.

Nuclear Fuel from Nuclear Waste: Formation of NewMOX SAS, France

Retrieved on: 
Thursday, April 4, 2024
Electricity, SAS, MOX, Uranium, ALD, Gesellschaft mit beschränkter Haftung, Area studies, Power plant engineering, Evonik Industries, AMG, CO2, Climate change, Nuclear energy, SMR, Plutonium, Coal, Engineering, Uranium mining

Amsterdam, 4 April 2024 --- AMG Critical Materials N.V. ("AMG", EURONEXT AMSTERDAM: "AMG") is pleased to announce the formation of NewMOX SAS, Grenoble, France, to service the nuclear fuel market.

Key Points: 
  • Amsterdam, 4 April 2024 --- AMG Critical Materials N.V. ("AMG", EURONEXT AMSTERDAM: "AMG") is pleased to announce the formation of NewMOX SAS, Grenoble, France, to service the nuclear fuel market.
  • Presently, the total global storage of civil-use plutonium resulting from the reprocessing of used fuel from commercial nuclear power operations stands at 380 tons, and this figure continues to grow with ongoing nuclear power generation.
  • “We are excited that our furnace technology engineering excellence has created a new project which resulted in the formation of NewMOX SAS.
  • We have appointed Serge Bertrand, head of ALD France, Grenoble, where ALD has centered its nuclear technology activities, to be CEO of NewMOX.

Aegon publishes its Integrated Annual Report 2023

Retrieved on: 
Thursday, April 4, 2024
Annual, Bank statement, Aegon, Annual report

The Hague, April 4, 2024 - Aegon Ltd. today published its Integrated Annual Report 2023.

Key Points: 
  • The Hague, April 4, 2024 - Aegon Ltd. today published its Integrated Annual Report 2023.
  • You can find out more about Aegon’s purpose and other topics covered in the Integrated Annual Report 2023 here , and the report can be downloaded via Aegon.com .
  • Aegon will also file its Annual Report 2023 on Form 20-F with the United States Securities and Exchange Commission (SEC).
  • The Annual Report 2023 on Form 20-F will be available later today on aegon.com and can be downloaded from the SEC website once filed.

Fortis Inc. to Hold Teleconference on May 1 to Discuss First Quarter 2024 Results and Hold Annual and Special Meeting on May 2

Retrieved on: 
Wednesday, April 3, 2024
Q&A, Webcast, Corporation, FTS, Shareholder, Special, Fortis, Broadcasting

ST. JOHN'S, Newfoundland and Labrador, April 03, 2024 (GLOBE NEWSWIRE) -- Fortis Inc. ("Fortis" or the "Corporation") (TSX/NYSE: FTS) will release its first quarter 2024 financial results on Wednesday, May 1, 2024.

Key Points: 
  • ST. JOHN'S, Newfoundland and Labrador, April 03, 2024 (GLOBE NEWSWIRE) -- Fortis Inc. ("Fortis" or the "Corporation") (TSX/NYSE: FTS) will release its first quarter 2024 financial results on Wednesday, May 1, 2024.
  • David Hutchens, President and Chief Executive Officer and Jocelyn Perry, Executive Vice President and Chief Financial Officer will discuss the Corporation's first quarter financial results.
  • A replay of the teleconference will be available two hours after the conclusion of the call until June 1, 2024.
  • Fortis will hold its 2024 Annual and Special Meeting of Shareholders on Thursday, May 2, 2024 at 9:00 a.m. (Eastern), 10:30 a.m. (Newfoundland), in-person and online.

QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024

Retrieved on: 
Wednesday, April 3, 2024
EGFR, Gene, Nested polymerase chain reaction, Professor, Cancer Institute, Circulating free DNA, Neoplasm, TCR, Research institute, QGEN, Research, PCR, Central business district, NGS, DNA, BRAF, Diagnosis, WIA, Cancer, Immune system, Liquid biopsy, UMI, Mutation, Genetics, Human genetics, Senior, AACR, Medical school, QIAGEN, Poster, Environment, IVD, Urine

Two Exhibitor Spotlight Theater sessions and several poster presentations will highlight additional advances from QIAGEN in this field.

Key Points: 
  • Two Exhibitor Spotlight Theater sessions and several poster presentations will highlight additional advances from QIAGEN in this field.
  • EGFR and BRAF are genes essential for normal cell growth and function, but mutations in these genes can result in cancer development.
  • To advance research on how the immune system interacts with cancer, QIAGEN has introduced the QIAseq Targeted RNA-seq Panel for T-cell receptors.
  • Learn more about QIAGEN’s offering at the AACR Annual Meeting 2024, (booth #922 in the San Diego Convention Center) and poster presentations highlighting new solutions in digital PCR, NGS and preanalytical workflows at https://www.qiagen.com/applications/cancer-research/aacr-2024-annual-mee... .

Irdeto partners with CharIN e.V. and takes on the “CharIN PKI”, Revolutionizing Public Key Infrastructure with Open Governance and Enhanced Security

Retrieved on: 
Wednesday, April 3, 2024
EV, Growth, EVS, Partnership, Seamless, Electric vehicle, ISO 15118, SVP, Plug, Combined Charging System, CONFIG.SYS, Fraud, API, OpenPlug, PKI, Certificate policy, Electric potential energy, ISO, Ecosystem, Online shopping

CharIN e.V., with their project members, created and aligned the first publicly established Governance for a PKI, including Certificate Policy, Governance, and market guidelines.

Key Points: 
  • CharIN e.V., with their project members, created and aligned the first publicly established Governance for a PKI, including Certificate Policy, Governance, and market guidelines.
  • Enhanced Security and Reliability: Irdeto’s expertise in cybersecurity is crucial for ensuring robust security within the Electric Vehicle (EV) charging infrastructure.
  • "As we embark on this exciting journey of taking over the CharIN Public Key Infrastructure., our focus remains steadfast on enhancing the EV charging experience through advanced security and a pioneering customer-inclusive governance model.
  • This moment marks not just a milestone for Irdeto, but a significant leap forward in the evolution of electric vehicle infrastructure.